This editorial addresses a clinically relevant and timely topic by extending the discussion of inflammation-based prognostic scoring in lenvatinib-treated hepatocellular carcinoma to modifiable host factors, particularly diet, exercise, nutritional status, and sarcopenia. Its main strength lies in emphasizing a more comprehensive, patient-centered interpretation of prognosis beyond numerical scores. However, as an editorial, its evidence level is inherently limited, and its academic impact would be strengthened by a more detailed appraisal of the original study’s methodology, confounding factors, and practical clinical implications. Overall, it is a meaningful and publishable editorial with good translational relevance.